Market Research

Alpha 1 Antitrypsin Deficiency Treatment Market by Treatment (Augmentation Therapy, Bronchodilators, Corticosteroids), Route of Administration (Inhalation, Injection, Oral), Distribution Channel - Global Forecast 2024-2030

Best Price Guarantee Length Publisher Published Date SKU
from $4,749 198 Pages 360iResearch January, 2024 IRE18418212
Best Price Guarantee
Price from $4,749
Length 198 Pages
Publisher 360iResearch
Published Date January, 2024
SKU IRE18418212

Alpha 1 Antitrypsin Deficiency Treatment Market by Treatment (Augmentation Therapy, Bronchodilators, Corticosteroids), Route of Administration (Inhalation, Injection, Oral), Distribution Channel - Global Forecast 2024-2030


The Alpha 1 Antitrypsin Deficiency Treatment Market size was estimated at USD 3.02 billion in 2023 and expected to reach USD 3.26 billion in 2024, at a CAGR 9.15% to reach USD 5.57 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Alpha 1 Antitrypsin Deficiency Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alpha 1 Antitrypsin Deficiency Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Alpha 1 Antitrypsin Deficiency Treatment Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc, Alnylam Pharmaceuticals, Inc., Apic Bio, Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Baxter International Inc., Cedars-Sinai Health System, Centessa Pharmaceuticals PLC, Chiesi Farmaceutici S.p.A., CSL Limited, Curaxys S.L., Dicerna Pharmaceuticals, Inc, GlaxoSmithKline PLC, Grifols, S.A., Inhibrx, Inc., Intellia Therapeutics, Inc., Kamada Ltd., Krystal Biotech, Inc., LFB Biomedicaments S.A., Mereo Biopharma Group PLC, Novo Nordisk A/S, Pfizer, Inc., PH PHARMA CO. LTD, Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Alpha 1 Antitrypsin Deficiency Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Treatment

Augmentation Therapy
  • Bronchodilators
  • Corticosteroids
  • Oxygen Therapy
  • Route of Administration

    Inhalation
  • Injection
  • Oral
  • Distribution Channel

    Offline

    Hospital Pharmacy
  • Retail Pharmacy
  • Online
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Alpha 1 Antitrypsin Deficiency Treatment Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alpha 1 Antitrypsin Deficiency Treatment Market?
    3. What are the technology trends and regulatory frameworks in the Alpha 1 Antitrypsin Deficiency Treatment Market?
    4. What is the market share of the leading vendors in the Alpha 1 Antitrypsin Deficiency Treatment Market?
    5. Which modes and strategic moves are suitable for entering the Alpha 1 Antitrypsin Deficiency Treatment Market?


    Note: PDF & Excel + Online Access - 1 Year


    • 1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Alpha 1 Antitrypsin Deficiency Treatment Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Rising incidences of alpha 1 antitrypsin deficiency among population
    5.1.1.2. Growing awareness about early diagnosis and preventive care
    5.1.2. Restraints
    5.1.2.1. High costs associated with R&D and dearth of skilled professionals
    5.1.3. Opportunities
    5.1.3.1. Emerging research on new alpha 1 antitrypsin deficiency treatments
    5.1.3.2. Increasing investments to modernize healthcare infrastructure
    5.1.4. Challenges
    5.1.4.1. Limitations associated with a diagnosis of alpha 1 antitrypsin deficiency
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Alpha 1 Antitrypsin Deficiency Treatment Market, by Treatment
    6.1. Introduction
    6.2. Augmentation Therapy
    6.3. Bronchodilators
    6.4. Corticosteroids
    6.5. Oxygen Therapy
    7. Alpha 1 Antitrypsin Deficiency Treatment Market, by Route of Administration
    7.1. Introduction
    7.2. Inhalation
    7.3. Injection
    7.4. Oral
    8. Alpha 1 Antitrypsin Deficiency Treatment Market, by Distribution Channel
    8.1. Introduction
    8.2. Offline
    8.3.1. Hospital Pharmacy
    8.3.2. Retail Pharmacy
    8.3. Online
    9. Americas Alpha 1 Antitrypsin Deficiency Treatment Market
    9.1. Introduction
    9.2. Argentina
    9.3. Brazil
    9.4. Canada
    9.5. Mexico
    9.6. United States
    10. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market
    10.1. Introduction
    10.2. Australia
    10.3. China
    10.4. India
    10.5. Indonesia
    10.6. Japan
    10.7. Malaysia
    10.8. Philippines
    10.9. Singapore
    10.10. South Korea
    10.11. Taiwan
    10.12. Thailand
    10.13. Vietnam
    11. Europe, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market
    11.1. Introduction
    11.2. Denmark
    11.3. Egypt
    11.4. Finland
    11.5. France
    11.6. Germany
    11.7. Israel
    11.8. Italy
    11.9. Netherlands
    11.10. Nigeria
    11.11. Norway
    11.12. Poland
    11.13. Qatar
    11.14. Russia
    11.15. Saudi Arabia
    11.16. South Africa
    11.17. Spain
    11.18. Sweden
    11.19. Switzerland
    11.20. Turkey
    11.21. United Arab Emirates
    11.22. United Kingdom
    12. Competitive Landscape
    12.1. FPNV Positioning Matrix
    12.2. Market Share Analysis, By Key Player
    12.3. Competitive Scenario Analysis, By Key Player
    13. Competitive Portfolio
    13.1. Key Company Profiles
    13.1.1. Abeona Therapeutics Inc
    13.1.2. Alnylam Pharmaceuticals, Inc.
    13.1.3. Apic Bio
    13.1.4. Arrowhead Pharmaceuticals, Inc.
    13.1.5. AstraZeneca PLC
    13.1.6. Baxter International Inc.
    13.1.7. Cedars-Sinai Health System
    13.1.8. Centessa Pharmaceuticals PLC
    13.1.9. Chiesi Farmaceutici S.p.A.
    13.1.10. CSL Limited
    13.1.11. Curaxys S.L.
    13.1.12. Dicerna Pharmaceuticals, Inc
    13.1.13. GlaxoSmithKline PLC
    13.1.14. Grifols, S.A.
    13.1.15. Inhibrx, Inc.
    13.1.16. Intellia Therapeutics, Inc.
    13.1.17. Kamada Ltd.
    13.1.18. Krystal Biotech, Inc.
    13.1.19. LFB Biomedicaments S.A.
    13.1.20. Mereo Biopharma Group PLC
    13.1.21. Novo Nordisk A/S
    13.1.22. Pfizer, Inc.
    13.1.23. PH PHARMA CO. LTD
    13.1.24. Takeda Pharmaceutical Company Limited
    13.1.25. Vertex Pharmaceuticals Incorporated
    13.2. Key Product Portfolio
    14. Appendix
    14.1. Discussion Guide
    14.2. License & Pricing
    FIGURE 1. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET RESEARCH PROCESS
    FIGURE 2. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2023 VS 2030
    FIGURE 3. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET DYNAMICS
    FIGURE 7. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
    FIGURE 8. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
    FIGURE 10. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
    FIGURE 12. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 14. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 16. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 18. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 21. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 22. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

    $4,749
    $5,749
    $6,749
    $8,749

    Research Assistance

    US: 800.298.5699
    Int'l: +1.240.747.3093
    Live help
    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Other tasks

    Cookie Settings